CTOs on the Move

Cellanyx

www.cellanyx.com

 
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cellanyx.com
  • 100 Cummings Center Suite 451C
    Beverly, MA USA 01915
  • Phone: 978.473.7883

Executives

Name Title Contact Details
Ashok Chander
Chief Technology Officer Profile

Similar Companies

M2 Communications

M2 Communications is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Summit Health

Summit Health is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Summit Health is based in Waynesboro, PA. You can find more information on Summit Health at www.summithealth.org

HemaCare Corporation

HemaCare Corporation is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.

Wish Recovery

Wish Recovery is a luxury rehab and detox facility in Los Angeles that offers personalized and comprehensive care for individuals struggling with alcohol and drug addiction.